HRP20120293T1 - Postupak smanjenja gastrointestinalne toksičnosti zbog primanja tegafura - Google Patents

Postupak smanjenja gastrointestinalne toksičnosti zbog primanja tegafura Download PDF

Info

Publication number
HRP20120293T1
HRP20120293T1 HR20120293T HRP20120293T HRP20120293T1 HR P20120293 T1 HRP20120293 T1 HR P20120293T1 HR 20120293 T HR20120293 T HR 20120293T HR P20120293 T HRP20120293 T HR P20120293T HR P20120293 T1 HRP20120293 T1 HR P20120293T1
Authority
HR
Croatia
Prior art keywords
tegafur
composition
treatment
oxonic acid
pharmaceutically acceptable
Prior art date
Application number
HR20120293T
Other languages
English (en)
Croatian (hr)
Inventor
Tahara Takeshi
Ambe Hiroshi
Kuritani Jun
Nomura Naruo
Original Assignee
Taiho Pharmaceutical Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co. filed Critical Taiho Pharmaceutical Co.
Publication of HRP20120293T1 publication Critical patent/HRP20120293T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20120293T 2004-04-29 2005-04-27 Postupak smanjenja gastrointestinalne toksičnosti zbog primanja tegafura HRP20120293T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (1)

Publication Number Publication Date
HRP20120293T1 true HRP20120293T1 (hr) 2012-04-30

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120293T HRP20120293T1 (hr) 2004-04-29 2005-04-27 Postupak smanjenja gastrointestinalne toksičnosti zbog primanja tegafura

Country Status (16)

Country Link
US (1) US20080166427A1 (enExample)
EP (1) EP1750703B1 (enExample)
JP (1) JP5376758B2 (enExample)
AT (1) ATE540679T1 (enExample)
AU (1) AU2005237364B2 (enExample)
CY (2) CY1112451T1 (enExample)
DK (1) DK1750703T3 (enExample)
ES (1) ES2378072T3 (enExample)
HR (1) HRP20120293T1 (enExample)
ME (1) ME01335B (enExample)
PL (1) PL1750703T3 (enExample)
PT (1) PT1750703E (enExample)
RS (1) RS52217B (enExample)
RU (1) RU2348409C2 (enExample)
SI (1) SI1750703T1 (enExample)
WO (1) WO2005105086A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
BR112012000873A2 (pt) * 2009-07-17 2019-11-05 Myriad Genetics Inc método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
MX383483B (es) * 2014-03-06 2025-03-14 Univ Southern California Utilización de régimen de ayuno a corto plazo en combinación con inhibidores de cinasa para potenciar la eficacia y viabilidad de fármacos quimioterápicos tradicionales e invertir los efectos secundarios de cinasas en células y tejidos normales.
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3122354B1 (en) 2014-03-28 2022-06-15 Universita' degli Studi di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
WO2016175324A1 (ja) * 2015-04-30 2016-11-03 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
KR20230012572A (ko) * 2020-05-19 2023-01-26 셀릭스 바이오 프라이빗 리미티드 암을 치료하기 위한 약학 제형 및 이의 제조

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1990007334A1 (fr) * 1989-01-05 1990-07-12 Otsuka Pharmaceutical Co., Ltd. Agent carcinostatique non injecte permettant de supprimer l'inflammation due a 5-fluorouracil, et procede de traitement du cancer
JP2614164B2 (ja) * 1991-05-27 1997-05-28 大鵬薬品工業株式会社 抗腫瘍効果増強のための及び腫瘍治療のための組成物
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect

Also Published As

Publication number Publication date
AU2005237364B2 (en) 2010-07-08
RS52217B (sr) 2012-10-31
ES2378072T3 (es) 2012-04-04
PT1750703E (pt) 2012-02-23
EP1750703A1 (en) 2007-02-14
EP1750703A4 (en) 2008-02-27
SI1750703T1 (sl) 2012-02-29
RU2348409C2 (ru) 2009-03-10
CY2012014I2 (el) 2016-04-13
WO2005105086A1 (en) 2005-11-10
RU2006142101A (ru) 2008-06-20
JP2007534634A (ja) 2007-11-29
CY1112451T1 (el) 2015-12-09
ME01335B (me) 2013-12-20
CY2012014I1 (el) 2016-04-13
JP5376758B2 (ja) 2013-12-25
ATE540679T1 (de) 2012-01-15
DK1750703T3 (da) 2012-05-07
AU2005237364A1 (en) 2005-11-10
US20080166427A1 (en) 2008-07-10
PL1750703T3 (pl) 2012-05-31
EP1750703B1 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
AU643976B2 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
HRP20120293T1 (hr) Postupak smanjenja gastrointestinalne toksičnosti zbog primanja tegafura
AU765749B2 (en) Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
JP2010525050A5 (enExample)
US7816366B2 (en) Compositions and methods for treating and preventing dermatoses
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
CN109152760B (zh) 胆汁淤积性和纤维化疾病的治疗方法
BRPI0518266A8 (pt) Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
HRP20250913T1 (hr) Nova upotreba kombinacije sakubitrila i valsartana
WO2021202245A1 (en) Viral treatment regimens
WO2008013630A3 (en) Calcium aluminosilicate pharmaceutical
US20080113949A1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
HU230890B1 (hu) Egy P2T receptor antagonistát és melagatrant tartalmazó gyógyszerkombinációk
WO2008074833A3 (en) Compounds
JP5416327B2 (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
EP2488642B1 (en) Compositions and methods for the treatment of drug-induced hand-foot syndrome
JP2007534634A5 (enExample)
WO2006117220A3 (en) Method of administering a cationic liposomal preparation comprising paclitaxel
JP2009500133A (ja) 全身抗癌療法のための定量および安全およびコンプライアンスパッケージング
JP2004534821A5 (enExample)
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
WO2007145993A3 (en) Modified compositions and methods for enhancing brain function
Lorenzen et al. CCR5 Antagonists in the Treatment of Treatment-experienced Patients Infects with CCR5 Tropic HIV-1
BRPI0510855A (pt) medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis
JP2025187628A (ja) 末期の膵臓がん患者の治療